The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article we look at what those investors think of Abbott Laboratories (NYSE:ABT).
Abbott Laboratories (NYSE:ABT) has experienced an increase in enthusiasm from smart money lately. Abbott Laboratories (NYSE:ABT) was in 63 hedge funds’ portfolios at the end of September. The all time high for this statistic is 67. There were 61 hedge funds in our database with ABT positions at the end of the second quarter. Our calculations also showed that ABT isn’t among the 30 most popular stocks among hedge funds (click for Q3 rankings).
At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium prices have more than doubled over the past year, so we go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. With all of this in mind we’re going to take a gander at the latest hedge fund action surrounding Abbott Laboratories (NYSE:ABT).
Ken Fisher of Fisher Asset Management
Do Hedge Funds Think ABT Is A Good Stock To Buy Now?
Heading into the fourth quarter of 2021, a total of 63 of the hedge funds tracked by Insider Monkey were long this stock, a change of 3% from the previous quarter. The graph below displays the number of hedge funds with bullish position in ABT over the last 25 quarters. With hedge funds’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were adding to their stakes considerably (or already accumulated large positions).
More specifically, Fisher Asset Management was the largest shareholder of Abbott Laboratories (NYSE:ABT), with a stake worth $989.5 million reported as of the end of September. Trailing Fisher Asset Management was BlueSpruce Investments, which amassed a stake valued at $473.3 million. Adage Capital Management, Two Sigma Advisors, and AQR Capital Management were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position BlueSpruce Investments allocated the biggest weight to Abbott Laboratories (NYSE:ABT), around 8.24% of its 13F portfolio. Sustainable Insight Capital Management is also relatively very bullish on the stock, setting aside 5.16 percent of its 13F equity portfolio to ABT.
As aggregate interest increased, some big names have jumped into Abbott Laboratories (NYSE:ABT) headfirst. Woodline Partners, managed by Michael Rockefeller and KarláKroeker, initiated the biggest position in Abbott Laboratories (NYSE:ABT). Woodline Partners had $69.2 million invested in the company at the end of the quarter. Renaissance Technologies also initiated a $27.8 million position during the quarter. The following funds were also among the new ABT investors: Anand Parekh’s Alyeska Investment Group, Michael Gelband’s ExodusPoint Capital, and Brandon Haley’s Holocene Advisors.
Let’s check out hedge fund activity in other stocks similar to Abbott Laboratories (NYSE:ABT). These stocks are PepsiCo, Inc. (NASDAQ:PEP), Accenture Plc (NYSE:ACN), Broadcom Inc (NASDAQ:AVGO), Costco Wholesale Corporation (NASDAQ:COST), Chevron Corporation (NYSE:CVX), AT&T Inc. (NYSE:T), and AbbVie Inc (NYSE:ABBV). This group of stocks’ market caps are similar to ABT’s market cap.
| Ticker | No of HFs with positions | Total Value of HF Positions (x1000) | Change in HF Position |
|---|---|---|---|
| PEP | 61 | 4435441 | -5 |
| ACN | 56 | 4460650 | 4 |
| AVGO | 50 | 2706386 | 3 |
| COST | 55 | 4393346 | 1 |
| CVX | 51 | 4442202 | 1 |
| T | 66 | 3212098 | -2 |
| ABBV | 81 | 4140050 | -1 |
| Average | 60 | 3970025 | 0.1 |
View table here if you experience formatting issues.
As you can see these stocks had an average of 60 hedge funds with bullish positions and the average amount invested in these stocks was $3970 million. That figure was $3612 million in ABT’s case. AbbVie Inc (NYSE:ABBV) is the most popular stock in this table. On the other hand Broadcom Inc (NASDAQ:AVGO) is the least popular one with only 50 bullish hedge fund positions. Abbott Laboratories (NYSE:ABT) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for ABT is 56.2. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 percentage points. These stocks gained 28.6% in 2021 through November 30th and still beat the market by 5.6 percentage points. Hedge funds were also right about betting on ABT as the stock returned 6.9% since the end of Q3 (through 11/30) and outperformed the market. Hedge funds were rewarded for their relative bullishness.
Follow Abbott Laboratories (NYSE:ABT)
Follow Abbott Laboratories (NYSE:ABT)
Suggested Articles:
- 11 Best Housing/Homebuilder Stocks To Buy Now
- 10 Best Cheap Stocks To Buy Now
- 19 Largest Construction Companies In the World
Disclosure: None. This article was originally published at Insider Monkey.
